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INTRODUCTION 
H. pylori is a helix-shaped gram negative, 
microaerophilic (i.e., it requires oxygen)    bacterium, 
mostly found in the stomach. It is one of the causes for 
gastritis, gastric ulcers, duodenal ulcers. 
1
 H. pylori used 
its flagella to burrow into the mucus lining of the 
stomach to reach the epithelial cells underneath where 
pH is more neutral. H. pylori is able to sense the pH 
gradient in the mucus and move towards the less acidic 
region (chemotaxins). The organisms H. pylori 
exclusively reside on the luminal surface of the gastric 
mucus under the mucus gut layer. 
2
 Therefore it becomes 
necessary to develop a drug delivery system, which can 
protect the drug from the gastric environment. The 
delivery system should be bioadhesive with a small 
particle size and at the same time it should target the 
drug to the bacterial cell lines. An important factor for 
bioadhesion is the particle size of the drug delivery 
sysem. Bioadhesive properties were optimized by a 
reduction of the size of the microparticulate and these 
improvements were attributed to several factors such as 
an increase of the adhesive forces, or a prolongation of 
the GI transit time leading to a higher bioavailability of 
drugs.
3
 
Gastroretentive drug delivery system like 
mucoadhesive microspheres system would improve the 
therapeutic effect of antimicrobial drugs. Microspheres 
are the carrier linked drug delivery system and are small 
spherical particles with diameter ranges from 1 μm to 
1000 μm. Microspheres constitute an important part of 
novel drug delivery system by virtue of their small size 
and efficient carrier capacity. Due to their short 
residence time, bioadhesive characteristics can be 
coupled to microspheres to develop mucoadhesive 
microspheres. Drug action can be improved by 
developing new drug delivery system, such as the 
mucoadhesive microsphere drug delivery system. These 
systems remain in close contact with the absorption 
tissue, the mucous membrane, releasing the drug at the 
action site leading to a bioavailability increase and both 
local and systemic effects. The oral route of drug 
administration constitutes the most convenient and 
preferred means of drug delivery to systemic circulation 
ABSTRACT 
The rationale of the present investigation is to develop a new oral drug delivery system utilizing both the concepts of controlled 
release and mucoadhesiveness, which could remain in stomach and control the drug release for longer period of time and thus 
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85.43%. In vitro drug release from Gelatin/ Acrypol microspheres showed more than 75% of the drug was released within 8 Hr, 
while pure drug showed complete drug release within 3 hours. This suggested controlled delivery of Levofloxacin for a longer 
period. Regression analysis revealed that the drug release from the microspheres was followed zero order kinetics. SEM images 
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of body. Mucoadhesive drug carriers may prolong the 
residence time in the gastrointestinal tract (GI) because 
they can adhere to the mucus surface, resulting in an 
effective localized drug concentration. 
4
 
Mucoadhesive drug carriers may prolong the 
residence time in the gastrointestinal tract because they 
can adhere to the mucus surface, resulting in an effective 
localized drug concentration. Among several 
mucoadhesive polymers, Acrypol usually has strong 
mucoadhesive properties and is known to be 
biocompatible and nontoxic.
4,5 
MATERIALS AND METHODS  
Materials  
Levofloxacin was a gift sample from SK Pharma, Sagar. 
Acrypol was a gift sample from Corel Pharma chem., 
Ahmedabad. Gelatin, Sun flower oil, Acetone, Diethyl 
ether, Glutaraldehyde, Concentrated Hydrochloric acid, 
Methanol were purchased from Sd fine chem. Limited, 
Mumbai. 
 Analytical Methods 
Absorption spectroscopy is one of the most valuable 
analytical techniques that is extensively used for 
qualitative and quantitative analysis of drugs. Although 
it has certain limitations, it has various advantages such 
as speed, simplicity, specificity and sensitivity. U.V. 
spectrophotometry was used for the analysis of 
Levofloxacin. An easy and simple spectrophotometric 
method is reported in literature which gives λmax for 
Levofloxacin 293 nm.
6 
UV Spectrophotometric Method 
Drug scaning
 
 
Pure 10mg of Levofloxacin was dissolved in 
100ml of 0.1N Hydrochloric acid. 0.8ml of this solution 
is further diluted to 10ml with same solvent to obtain 
8µg/ml Levofloxacin solution. Scanned 
spectroscopically in the wavelength region 200 to 
400nm. The determined wave length of maximum 
absorption was at 293nm. 
  
 
 
 
Figure 1: Scan for Levofloxacin solution (8µg/ml) in 0.1N Hydrochloric acid 
 
Calibration curve of Levofloxacin in 0.1N 
Hydrochloric acid solution 
6
 
 Stock solution:  Pure Levofloxacin 50mg was 
dissolved in 100ml of 0.1N Hydrochloric acid. 5ml of 
this solution was further diluted to 100ml with same 
solvent to obtain 25µg/ml.  
 Working solution: From the stock solution (25µg/ml) 
suitable working solution of different concentrations of 
2, 4, 6, 8 & 10µg/ml were made. The absorbance of 
these dilutions was measured at 293nm. The standard 
graph of concentration versus absorbance was then 
plotted. Plot is shown in Figure 1.  Each point is an 
average of three determinations. Slope, y-axis intercept, 
and regression coefficients were calculated. Table 1 
shows the data for Standard plot of Levofloxacin in 
0.1N hydrochloric acid solution.  
Characterization of Levofloxacin  
Melting point 
7
  
The melting point of the Levofloxacin was 
determined using capillary tubes. One end of the 
capillary tube was sealed. The sample was filled and 
placed in the melting point apparatus.  The melting point 
was noted.        
FT-IR studies 
7
 
Levofloxacin was added to the powdered 
potassium bromide in the ratio of 1:100. The mixture 
was compacted under pressure (10 tons/cm
2
) in vacuum 
to form a transparent pellet. The spectra were obtained 
by placing the pellet in the IR chamber and the peak 
intensities were taken.  
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Drug - Excipient Compatibiliy Studies By FT- IR 
Studies
7 
The study of drug- excipient compatibility is an 
important stage in the development of a dosage form as 
their incompatibiliy can alter the stability and/or the 
bioavailability of drugs thereby, affecting its safety 
and/or efficacy. Drug- excipient compatibility was 
performed by FTIR analysis. 
FTIR spectra of physical mixture Levofloxacin 
(drug) and Gelatin+ Acrypol 934P (excipients) (1:1) 
ratio recorded on Shimadzu FTIR Spectrophotometer. 
Sample was added to the powdered potassium bromide 
in the ratio of 1:100.   The mixture was compacted 
under pressure (10 tons/cm
2
) in vacuum to form a 
transparent pellet. The spectra were obtained by placing 
the pellet in the IR chamber and the peak intensities 
were taken. The characteristic bands of mixture with 
excipients were compared with pure drug. 
Formulation and Development
8
 
Preparation of Gelatin/ Acrypol 934P mucoadhesive 
microspheres by emulsification cross linking method 
 An aqueous 15ml of 20% aqueous Gelatin 
solution was prepared by heating at 55- 60˚C. 1000mg 
of drug was added to the phase. The aqueous phase was 
emulsified with 100ml of sunflower oil, previously 
heated to 55- 60
o
C and the mixture was stirred at 1000 
RPM for 5min using mechanical stirrer. To this 
emulsion, Acrypol 934P (different % with respect to 
gelatin mass) was added and stirring was prolonged for 
further 5min. The cross- linker Glutaraldehyde was 
added to the emulsion. The prepared Gelatin droplets 
were solidified by a fast cooling process under stirring 
for 30min. Dehydration was carried out by adding 75ml 
of acetone under stirring for 5min. The microspheres 
were separated by filtration and washed 3 times with 
50ml of Diethyl ether.  
The formulation variables in the preparation of 
Gelatin/ Acrypol 934P microspheres are tabulated in the 
Table 1. In the composition of Gelatin/ Acrypol 934P 
microspheres, Acrypol 934P concentration and stirring 
speed was varied and remaining formulation variables 
like Gelatin solution, sun flower oil, Glutaraldehyde, 
Acetone, Diethyl ether and drug amount were kept 
constant.
 
Table 1: Composition of Gelatin/ Acrypol 934P microspheres formulation to study the effect of Acrypol 934P 
concentration & stirring speed 
 
Formulation variables GA1 
 
GA2 GA3 GA4 GA5 
Gelatin solution %(w/w) 20% 20% 20% 20% 20% 
Sun flower oil (ml) 100ml 100ml 100ml 100ml 100ml 
Acrypol 934P (%) 0.5% 1% 2% 1% 1% 
Speed (RPM) 500RPM 500 RPM 500 RPM 1000 RPM 1500 RPM 
Gluteraldehyde (%) 1% 1% 1% 1% 1% 
Acetone (ml) 75ml 75ml 75ml 75ml 75ml 
Diethyl ether (ml) 50ml 50ml 50ml 50ml 50ml 
Drug (mg) 1000mg 1000mg 1000mg 1000mg 1000mg 
    
Optimization of process variables of prepared system 
         A preparation Gelatin / Acrypol 934P microsphere 
involves various process variables, out of which the 
following variables were selected: 
(a) Effect of Acrypol 934P concentration. 
(b) Effect of Gluteraldehyde concentration. 
(c) Effect of stirring speed. 
Effects of these variables were observed on final particle 
size distribution of microspheres. 
Evaluation of Mucoadhesive Microspheres 
Shape and surface morphology 
9 
Optical photomicrograph 
Microspheres suspension was mounted on glass 
slide and observed under the optical microscope for their 
shape. The photomicrographs of both the system are 
shown in the Figure 7.  
SEM analysis 
The surface morphology was visualized by 
Scanning Electron Microscopy (SEM). The samples for 
SEM were prepared by lightly sprinkling the 
microsphere powder on a double adhesive tape, which 
stuck to an aluminium stub. The stubs were then coated 
with gold a thickness of about 300A˚ using a sputter 
coater. The samples were then randomly scanned and 
photographs were taken. SEM photographs of the 
microspheres system is shown in Figure 8 SEM analysis 
was done using HITACHI S-3700N SEM analysis 
instrument. It was done to study surface morphology 
(shape) of microspheres. 
Particle size analysis 
19
 
Particle size was studied using optical 
microscope, consisting of eye piece and stage 
micrometer. Calibration factor was calculated then 
microspheres were placed on the slide using Liquid 
Paraffin and size was observed. The particle diameters 
of 100 microspheres were measured randomly by optical 
microscope. 
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               Average particle size = Σnd/Σn  
Here     ∑nd = sum of product of frequency & diameter 
              ∑n = total no. of spheres counted  
Percentage yield 
10
 
Microspheres dried at room temperature were 
weighed and the yield of microspheres preparation was 
calculated by using formula:  
Percentage yield = [Practical Yield / Theoretical Yield] 
x 100 
Drug entrapment efficiency 
11
 
200 mg of accurately weighed microspheres 
were crushed in a glass mortar and the powdered 
microspheres were suspended in 10 ml of 0.1 N 
Hydrochloric acid (pH = 1.2). After 24h, the solution 
was filtered and the filtrate was analysed for the drug 
content. The drug entrapment efficiency was calculated 
using the following formula: 
 
In- vitro wash off test for mucoadhesion 
12
 
The mucoadhesive property of microspheres 
was evaluated by in- vitro wash off test for 
mucoadhesion.  Pieces of goat stomach mucosa were 
mounted onto glass slides using thread. 100mg of 
microspheres were spread onto each wet rinse tissue 
specimen. Immediately thereafter the support was hung 
onto the arm of USP Disintegration test machine. By 
operating the disintegrating test machine, the tissue 
specimen was given a regular up and down movement in 
0.1N Hydrochloric acid at 37˚C. At the end of one hour 
the machine was stopped and the microspheres in the 
0.1N Hydrochloric acid was centrifused, dried and 
weighed. The mucoadhesivity of these microspheres was 
calculated by the following formula: 
Percentage Mucoadhesivity=   
Wt. of adhered microspheres 
  x 100 
                                                  
Wt. of applied microspheres
  
 In- vitro drug release studies
12 
The drug release study was performed using 
USP paddle apparatus at 37°C±0.5°C and at 100 RPM 
using 900 ml of 0.1N Hydrochloric acid as a dissolution 
medium.  300mg of microspheres containing 100mg of 
pure drug were filled in “0” size hard gelatin capsules 
were placed in dissolution medium. Perfect sink 
conditions prevailed during the drug dissolution tests.  5 
ml of sample solution was withdrawn at predetermined 
time intervals and the absorbance of the sample was 
recorded using UV spectrophotomerically at 293nm. The 
same experiment was conducted for pure drug 
Levofloxacin (100 mg).  
Drug Release Kinetics
13
  
Drug released from the dosage forms follow the 
different kinetics rules. The release of the drug from the 
different dosage forms depends on the various factors 
like concentration, temperature, light and also the 
rotating speed of the paddle. There are several 
mathematical models of release kinetics. Some are 
described below. 
Zero-order model 
Drug dissolution from dosage forms that do not 
disaggregate and release the drug slowly can be 
represented by the equation: 
Q0 – Qt = K0t 
Rearrangement 
Qt = Q0 + K t 
Where, Qt is the amount of drug dissolved in 
time t. Q0 is the initial amount of drug in the solution 
(most times, Q0=0) and K0 is the zero order release 
constant expressed in units of concentration/time. 
To study the release kinetics, data obtained 
from in vitro drug release studies were plotted as 
cumulative amount of drug released versus time. 
Application: This relationship can be used to describe 
the drug dissolution of several types of modified release 
pharmaceutical dosage forms, as in the case of some 
transdermal systems, as well as matrix tablets with low 
soluble drugs in coated forms, osmotic systems, etc. 
First order model 
This model has also been used to describe 
absorption and/or elimination of some drugs, although it 
is difficult to conceptualize this mechanism on a 
theoretical basis. The release of the drug which followed 
first order kinetics can be expressed by the equation: 
dc/ dt = -kc 
Where k is the first order rate constant expressed in units 
of time 
-1.
 
This equation can be expressed as: 
log C = log C0 – Kt / 2.303 
Where, C0 is the initial concentration of drug, k is the 
first order rate constant and t is the time. 
The data obtained are plotted as log cumulative 
percentage of drug remaining verses time which would 
yield a straight line with a slope of –K/2.303. 
Application: this relationship can be used to describe the 
drug dissolution in pharmaceutical dosage forms such as 
those containing water-soluble drugs in porous matrices. 
 Higuchi Model 
The first example of a mathematical model 
aimed to describe drug release from a matrix system was 
proposed by Higuchi in 1961. Initially conceived for 
planar systems, it was then extended to different 
geometrics and porous systems. 
This model is based on the hypotheses that (i) 
initial drug concentration in the matrix is much higher 
than drug solubility; (ii) drug diffusion takes place only 
in one dimension (edge effect must be negligible); (iii) 
drug particles are much smaller than system thickness; 
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(iv) matrix swelling and dissolution are negligible; (v) 
drug diffusivity is constant; and (vi) perfect sink 
conditions are always attained in the release 
environment. Accordingly, model expression is given by 
the equation:  
Ft = Q = AD             
Where Q is the amount of drug released in time 
t per unit area A, C is the drug initial concentration, Cs 
is the drug solubility in the matrix media and D is the 
diffusivity of the drug molecules (diffusion coefficient) 
in the matrix substance. To study the dissolution from a 
planar heterogeneous matrix system, where the drug 
concentration in the matrix is lower than its solubility 
and the release occurs through pores in the matrix, the 
expression is given by equation. 
ft = Q = 
  
 
              
where, D is the diffusion coefficient of the drug 
molecule in the solvent, δ is the porosity of the matrix,   
is the tortuisity of the matrix and Q, A, Cs and t have the 
meaning assigned above. Tortuisity is defined as the 
dimensions of radius and branching of the pores and 
canals in the matrix. In a general way it is possible to 
simplify the Higuchi model as (generally known as the 
simplified Higuchi model): 
ft = Q = KH  .t
1/2 
Where, KH is the Higuchi dissolution constant. 
The data obtained were plotted as cumulative 
percentage drug release versus square root of time. 
Application: This relationship can be used to describe 
the drug dissolution from several types of modified 
release pharmaceutical dosage forms, as in the case of 
some transdermal systems and matrix tablets with water 
soluble drugs.  
Hixson-Crowell model 
Hixson and Crowell (1931) recognized that the particles 
regular area is proportional to the cube root of its 
volume. They derived the equation: 
W0
1/3
 – Wt1/3 = Kst 
Where, W0 is the initial amount of drug in the 
pharmaceutical dosage form, Wt is the remaining 
amount of drug in the pharmaceutical dosage form at 
time t and k (kappa) is a constant incorporating the 
surface volume relation. The equation describes the 
release from systems where there is a change in surface 
area and diameter of particles or tablets. 
To study the release kinetics, data obtained from in vitro 
drug release studies were plotted as cube root of drug 
percentage remaining in matrix versus time. 
Application: this expression applies to pharmaceutical 
dosage form such as tablets, where the dissolution 
occurs in planes that are parallel to the drug surface if 
the tablet dimensions diminish proportionally, in such a 
manner that the initial geometrical form keeps constant 
all the time.  
The regression analysis of the experimental 
data was done using statistical functions of the MS-
EXCEL program. 
RESULTS AND DISCUSSION 
Standard curve of Levofloxacin: The λmax of 
Levofloxacin in 0.1N Hydrochloric acid at 293nm as 
shown in Figure 1. Considering this λmax, a calibration 
curve of Levofloxacin in the Figure 2 was frabricated 
using the data obtained Table 2. The standard graph 
constructed conferred that the concentrations of drug 
ranging from 2 to 8 μg/ml obeyed the Beer- Lambert 
principle. Moreover, the calibration curve of 
Levofloxacin exihibited a good correlation between the 
concentrations and absorbance in this range (R
2
= 0.999). 
Table 2: Data for standard curve of Levofloxacin in 
0.1N Hydrochloric acid at 293 nm 
*= Each value is average of three determinations 
 
 
Figure 2: Standard curve of Levofloxacin in 0.1N 
Hydrochloric acid at 293nm 
Characterization of Levofloxacin 
Melting point 
7 
The melting point of the Levofloxacin was found to be 
212˚C. In Literature, melting point of Levofloxacin was 
reported to be 214- 216
o
C. This facilitated the 
identification of Levofloxacin. The result of melting 
point determination was reported in Table 3. 
Concentration 
(µg/ml) 
Absorbance 
AM* ± S.D 
0 0.0±0.00 
2 0.220±0.016 
4 0.459±0.011 
6 0.687±0.028 
8 0.915±0.027 
10 1.33±0.024 
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Table 3: Melting point of Levofloxacin 
Melting point of 
Levofloxacin 
Literature value
7
 Observed value 
214- 216˚C 212˚C 
 
FT-IR studies
7 
 
 
Figure 3: FT- IR Spectra of Levofloxacin 
The observed characteristic absorption peaks of Levofloxacin were compared with the literature data shown in Table 4. 
There are three characterization peaks at 1722.43cm
-1
 of carbonyl C=O, 2881.65cm
-1
 of aromatic C-H and 3261.63cm
-1
. 
The Figure 3 indicating the characteristic peaks of the drug Levofloxacin match with that of the literature data.  
Table 4: Comparison of characteristic IR bands between literature and observed values of Levofloxacin pure 
drug 
Characteristic bands Literature values
7
, cm
-1
 Observed values, cm
-1
 
Carboxyl, C=O 1724.81 cm
-1
 1722.43 cm
-1
 
Aromatic, C-H 2935.62 cm
-1
 2881.65 cm
-1
 
O-H group of carboxyl (-COOH) moiety 3265.81 cm
-1
 3261.63 cm
-1
 
 
Drug-Excipient Compatibiliy Studies by FT- IR Studies
7 
 
Table 4 indicated the three characterization peaks for Levofloxacin reported at 1722.43cm
-1
 of carbonyl C=O, at 
2883.58cm
-1
 of aromatic C-H and at 3261.81cm
-1 
of carbonyl –COOH moiety . The comparision of characteristic peaks 
in the spectra of drug (Table 4 and Figure 3) with the characteristic peaks in the spectra of polymers Gelatin and 
Acrypol 934P (Table 5 and Figure 4) reveals no drug excipients interaction.  
 
 
Figure 4: FT- IR Spectrum of physical mixture Levofloxacin+ Gelatin+ Acrypol 934P 
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Table 5: Compatibility study of Levofloxacin with Gelatin & Acrypol 934P 
Characteristic Bands 
cm
-1
 
Levofloxacin 
Observed 
values cm
-1
 
Physical mixture of Levofloxacin+ Gelatin+ 
Acrypol 934P Observed 
values cm
-1
 
Carboxyl, C=O 1722.43 cm
-1
 1722.43 cm
-1
 
Aromatic, C-H 2883.58cm
-1
 2881.65 cm
-1
 
O-H group of carboxyl 
(-COOH) moiety 
3261.63 cm
-1
 3261.63 cm
-1
 
 
Gelatin/ Acrypol Mucoadhesive Microspheres 
Mucoadhesive Gelatin/ Acrypol 934P microspheres were prepared by Emulsification cross linking method. 
Hardening of microspheres was performed by chemical cross-linking with Glutaraldehyde.  
Optimization of Process Variables of Gelatin/Acrypol Microspheres 
Effect of Acrypol 934P concentration  
Table 6: Effect of Acrypol 934P on average particle size of Gelatin / Acrypol 934P microspheres 
     Formulation 
(Acrypol 934P 
concentration) 
  Mean diameter 
(µm) 
    Frequency 
(n) 
 Average particle size 
(µm) 
 
GA1 
0.5% 
43 
79 
115 
151 
23 
52 
25 
0 
 
70.6µm 
 
GA2 
1% 
 
43 
79 
115 
151 
32 
55 
7 
6 
 
81µm 
 
GA3 
2% 
43 
79 
115 
151 
18 
43 
29 
10 
 
101.6µm 
 
 
 
 
Figure 5: Plot for effect of Acrypol 934P 
concentration (with respect to Gelatin mass) on 
Gelatin / Acrypol 934P microspheres 
The Gelatin/Acrypol microspheres were 
prepared using varying concentrations of Acrypol 934P 
(0.5% to 2% with respect to gelatin concentration). The 
effect of Acrypol 934P concentration on average particle 
size was observed. The data was tabulated in Table 6. 
The particle size for Gelatin/Acrypol 934P 
microspheres was found to be in the range of 35 µm to 
101.6 µm. A direct relationship was observed between 
polymer concentration and particle size.  Particle size 
was maximum for formulation GA3 (with Acrypol 934P 
concentration 2%) whereas found to be least for 
formulation GA1 (with Acrypol 934P concentration 
0.5%). Acrypol concentration did not show any 
remarkable effect on size distribution. Rather it showed 
a significant effect on bioadhesive property and in vitro 
drug release. 
Effect of stirring speed 
The effect of varying stirring speed (500 RPM 
to 1500 RPM) on the particle size and size distribution 
of Gelatin / Acrypol 934P microspheres was observed 
and was reported in the Table 7. There was an inverse 
relationship found between the stirring speed and 
average particle size. The mean diameter of 
microspheres decreased from 81 to 35μm with 
increasing stirring speed from 500 to 1500 RPM as 
reported in the Table 7 and Figure 6. Results revealed 
that the average diameter of microspheres was 
controlled by rotational speed. The smallest particle size 
was observed with 1500 RPM but the prepared 
microspheres adhered to the blades of stirrer and lumps 
were formed. Hence optimized stirring speed was 
considered as 1000 RPM although the average particle 
size was least with 1500 RPM. 
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Table 7: Effect of stirring speed on Gelatin / Acrypol 934P microspheres 
      Formulation 
(Stirring speed 
and 
Gluteraldehyde 
concentration) 
 
 
Mean diameter 
(µm) 
 
 
Frequency(n) 
 
 
Average particle size 
(µm) 
 
GA2 
500 RPM 
1% 
50 
60 
105 
150 
0 
32 
55 
13 
 
81µm 
 
 
GA4 
1000 RPM 
1% 
50 
60 
105 
150 
25 
49 
26 
0 
 
41.5µm 
 
GA5 
1500 RPM 
1% 
50 
60 
105 
150 
10 
90 
0 
0 
 
35µm 
 
  
 
Figure 6: Plot showing effect of stirring speed on 
Gelatin / Acrypol 934P microspheres 
Preparation of Gelatin/Acrypol 934p Mucoadhesive 
Microspheres 
Gelatin/Acrypol microspheres were 
successfully prepared by emulsification cross linking 
method. The microspheres produced were spherical. 
Finally optimized formula was reported in Table 8.  
The effect of various process variables such as 
stirring speed and polymer concentration were 
optimized. The Gelatin/ Acrypol microspheres were 
prepared using varying concentrations of Acrypol 934P 
(0.5% to 2% with respect to gelatin concentration). The 
particle size for Gelatin/ Acrypol 934P microspheres 
was increased with higher concentrations of Acrypol 
polymer and found to be in the range of 70.6 µm to 
101.6 µm. Acrypol concentrations did not show any 
remarkable effect on size distribution. 
The mean diameter of microspheres decreased 
from 101 to 35μm with increasing stirring speed from 
500 to 1500 RPM. Results suggested that the stirring 
speed of 1000 RPM was found to be optimum for 
Gelatin/ Acrypol 934P microspheres.  
Table 8: Finally optimized formulation [GA4] for 
Gelatin/ Acrypol 934P microspheres 
Formulation variables Parameters 
Gelatin solution (%) 20 % 
Sun flower oil (ml) 100 ml 
Acrypol 934P (%) 1 % 
Stirring speed (RPM) 1000 RPM 
Glutaraldehyde (%) 1 % 
Acetone (ml) 75 ml 
Diethyl ether (ml) 50 ml 
Drug (mg) 1000 mg 
 
Evaluation Tests of Gelatin/Acrypol Microspheres 
Particle Shape and surface morphology 
Optical microscopy  
Microspheres suspension in liquid paraffin was mounted 
on glass slide and observed under the optical 
microscope for their shape. The optical 
photomicrograph of Gelatin/ Acrypol microspheres was 
shown in the Figure 7. Photomicrograph suggested the 
spherical structure with a smooth surface.  
 
 
Figure 7: Optical photomicrograph of Gelatin/ 
Acrypol microspheres 
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SEM analysis  
The surface morphology was visualized by 
Scaning Electron Microscopy. SEM analysis photograph 
of Gelatin/ Acrypol microspheres was shown in the 
Figure 8. 
Shape and morphology of the particles was 
observed in SEM photographs. Figure 8 shows the 
spherical structure with a smooth surface of Gelatin/ 
Acrypol 934 P microspheres (Formulation GA4). The 
optimized formulation GA4 was showed average 
particle size of 41.5 µm.  
Figure 8: SEM analysis photograph of Gelatin/ 
Acrypol microspheres (Formulation GA4)
 
Average particle size 
Table 9:  Average particle size of Gelatin/ Acrypol microspheres 
Formulation 
Code 
    Polymer 
concentration 
(%) 
Glutaraldehyde   
concentration 
(%) 
     Stirring 
speed 
(RPM) 
Average particle size 
(µm) 
(AM*± S.D ) 
GA1 0.5% 1% 500RPM 70.6±0.065µm 
GA2 1% 1% 500RPM 81±0.026µm 
GA3 2% 1% 500RPM 101.6±0.35µm 
GA4 1% 1% 1000RPM 41.5±0.054µm 
GA5 1% 1% 1500RPM 35±0.057µm 
*= Each value is average of three determinations 
 
 
Figure 9: Average particle size of Gelatin/ Acrypol 
microspheres formulations 
The size and size distribution of microspheres 
were determined by optical microscopy. The average 
particle size  for Gelatin/ Acrypol 934P microspheres 
was tabulated in the Table 9 and reported as a bar 
diagram in Figure 9. For formulations GA1, GA2 and 
GA3 the Glutaraldehyde concentration (1%) and stirring 
speed (500 RPM) were constant with varying polymer 
concentration. No much difference was seen in average 
particle size for the above three formulations (GA1, 
GA2 & GA3) suggesting that there is no direct effect of 
polymer concentration on particle size of microspheres. 
For formulations GA2, GA4 and GA5 the 
polymer concentration (1%) and Glutaraldehyde 
concentration (1%) were constant with varying stirring 
speed from 500 to 1500 RPM. There was an inverse 
relationship found between the stirring speed and 
average particle size. The formulation GA5 with highest 
stirring speed 1500 RPM had smallest particle size of 
35μm.  
The average particle size (μm) of microspheres 
decreased (Figure 9) from 101 to 35μm with increasing 
stirring speed from 500 to 1500 RPM. 
Percentage yield and Drug entrapment efficiency for 
Gelatin/ Acrypol microspheres 
The percentage yield and  drug entrapment 
efficiency for Gelatin/ Acrypol microspheres was 
tabulated in the Table 10 and represented as a bar 
diagram in Figure 10. 
The percentage yield for all five Gelatin/ 
Acrypol 934P microspheres formulation was found in 
the range of 91.5 to 95.8%. The maximum percentage 
yield was found with formulation GA4 (94.6%). 
The percentage drug entrapment efficiency of 
the Gelatin/ Acrypol 934P microspheres was 
represented in Figure 11. 
Various drug loaded formulations were 
prepared by using optimized parameters and studied for 
percentage drug entrapment efficiency.  The results 
indicating that as the Acrypol 934P concentration 
increased from 0.5 to 2% the percentage drug 
entrapment efficiency was increased from 69.25 to 
85.43%. The maximum percentage drug entrapment 
efficiency was shown for (GA4) formulation i.e., 
85.43% with Acrypol 934P concentration of 1%. 
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Table 10: Percentage yield and Drug entrapment efficiency for Gelatin/ Acrypol microspheres 
*= Each value is average of three determinations 
 
 
Figure 10: Chart for percentage yield of Gelatin/ 
Acrypol 934P microspheres formulations 
 
 
Figure 11: Percentage Drug entrapment efficiency of 
Gelatin/ Acrypol microspheres formulations 
In- vitro wash off test 
Table 11: Percentage mucoadhesivity of 
Gelatin/Acrypol microspheres formulations 
Formulation code Percentage 
mucoadhesivity 
GA1 81% 
GA2 85.4% 
GA3 90.8% 
GA4 86.6% 
GA5 87.5% 
 
The percentage mucoadhesivity of Gelatin/Acrypol 
microspheres formulations was reported in the Table 11. 
The percentage mucoadhesivity for Gelatin/Acrypol 
microspheres formulations was shown in the Figure 12. 
 
 
Figure 12: Percentage mucoadhesivity for Gelatin/ 
Acrypol microspheres formulations 
 
The Gelatin/ Acrypol 934P microspheres were prepared 
by using Gelatin and Acrypol 934P using different 
concentrations of Acrypol with an intention to increase 
the mucoadhesion. The percentage mucoadhesivity of 
Gelatin/ Acrypol 934P microspheres were found to be 
increased from 81% to 90.8% as the concentration of 
Acrypol was increased from 0.5% to 2%. There was a 
forward relationship was found between Acrypol 934P 
and percentage mucoadhesivity. The highest percentage 
mucoadhesivity was recorded in GA3 i.e., 90.8% among 
all formulations because highest concentration of 
Acrypol 934P i.e., 2% was used in GA3 formulation. 
Optimized formulation GA4 was showing 86.6% 
mucoadhesivity. The results clearly showed Table 11 
and Figure 12 that surface modification of Gelatin/ 
Acrypol 934P microspheres greatly enhanced the 
mucoadhesive property. 
When Acrypol 934P was blended with Gelatin, 
the bioadhesive properties of Acrypol 934P also 
contributed to overall mucoadhesive capacity of the 
system (Gelatin- Acrypol 934P microspheres). The 
carbonyl group of Acrypol 934P provides site for H- 
bond interaction with sialic acid –COOH group in the 
mucin glycoprotein. Thus blending of Acrypol 934P 
with gelatin greatly enhanced the mucoadhesive 
property.
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Formulation code 
 
Percentage yield Percentage drug entrapment efficiency 
(AM*± S.D ) 
GA1 95.8% 69.25±0.087% 
GA2 93.6% 73.46±0.058% 
GA3 91.5% 80.02±0.054% 
GA4 94.6% 85.43±0.036% 
GA5 93.4% 71.8±0.45% 
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In vitro percentage drug release profile of Gelatin/ Acrypol microspheres 
Table 12: In vitro percentage drug release profile of Gelatin/ Acrypol microspheres and pure drug 
(Levofloxacin) in 0.1N Hydrochloric acid. 
Time  
(hrs) 
Cumulative percentage drug release (AM*± S.D ) 
Pure drug GA1 GA2 GA3 GA4 GA5 
1 hr 73.2±1.26 25.8±0.056 19.7±0.59 21.4±0.97 21±0.28 20.3±0.94 
2 hr 90.7±0.55 39.4±0.54 23.9±0.064 28.3±0.67 25.6±0.38 24.5±0.61 
3 hr 100±0.07 46.9±0.83 37.6±0.46 37.6±0.67 43.3±0.25 34.5±0.46 
4 hr - 55.4±0.52 45.5±0.13 48.7±0.76 53.5±0.12 39.9±0.45 
5 hr - 61.5±0.58 51.3±0.48 55.7±0.45 61.7±0.47 45.6±0.73 
6 hr - 67.8±0.27 57±0.82 66.1±0.45 67.2±0.92 65.3±0.42 
7 hr - 71.5±0.57 64.9±0.54 74±0.82 75.2±0.47 65.3±0.42 
8 hr - 80.1±0.42 70.9±0.57 84.5±0.67 85.3±0.44 76.4±0.33 
*= Each value is average of three determinations 
 
 
Figure 13: Plot for In vitro cumulative percentage 
drug release of Gelatin/ Acrypol microspheres in 
0.1N Hydrochloric acid. 
The in vitro dissolution study was carried out in 
USP dissolution apparatus by paddle method. Since the 
stomach pH is between 1 and 3, an acidic medium 0.1N 
Hydrochloric acid (1.2 pH) was used for dissolution 
studies. The in vitro percentage drug release profile of 
Gelatin/ Acrypol microspheres and pure drug 
(Levofloxacin) in 0.1N Hydrochloric acid was tabulated 
in the Table 12 and represented in Figure 13. 
The pure drug release was found to be 73.8% in 
first hour of dissolution test and complete drug release 
of total content of capsule was within 3 hours. The 
release of Levofloxacin from the microspheres follows 
diffusion or erosion mechanisms through matrix. Thus 
as long as there is sufficient drug solubility, these 
mechanism control drug release. A perusal of Figure 13 
indicated slow release of Levofloxacin from the 
formulations.  
The influence of concentration of Acrypol 
934P on the release from Gelatin/ Acrypol 934P 
microspheres indicating that drug release increased with 
increasing Acrypol concentration from 0.5 to 2%, 
because the amount of swelling was greater for 
microspheres with higher Acrypol content and the 
swelling is the principle factor for drug release. The in 
vitro release profile of different microspheres 
formulations are shown in Figure 13. It was observed 
that from microspheres formulation sustained drug 
release was achieved when compared with the pure 
drug. 
Drug Release Kinetics 
The release kinetics of the various formulations was 
determined to understand the order of drug release. The 
drug release kinetics of the formulations was determined 
in 0.1N hydrochloric acid solution and the results are 
shown in the Table 13 and Figure 14. The release kinetic 
data indicated that all formulations showed zero order 
release kinetics (high R
2
 value for zero order). 
The kinetics of drug release from Gelatin/ Acrypol 934P 
microspheres formulation (GA4) follows zero order 
(high R
2 
value) suggesting controlled release of drug.
 
Table 13: Release kinetics data of different Gelatin/ Acrypol microspheres formulations. 
  
Formulation 
code 
Zero order First order Higuchi Hixon-Crowell 
K0 R
2
 K1 R
2
 Kd R
2 
Khc R
2 
GA1 8.815 0.960 0.158 0.731 27.94 0.999 0.375 0.774 
GA2 0.133 0.930 0.00 0.00 0.00 0.00 0.380 0.818 
GA3 9.825 0.992 0.170 0.789 29.57 0.980 0.404 0.833 
GA4 10.09 0.973 0.172 0.789 30.64 0.982 0.411 0.832 
GA5 8.518 0.988 0.164 0.789 25.48 0.970 0.382 0.829 
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Figure 14: Plot for zero order kinetics of in vitro 
release of Levofloxacin from Gelatin/ Acrypol 934P 
microspheres formulation (GA4). 
   
 CONCLUSION 
The conclusions drawn from the present work 
are drug selected for the present work was Levofloxacin. 
It was estimated spectrophotometrically scanned at λ 
max 293 nm. Standard curves for the drug were prepared 
in 0.1N Hydrochloric acid. The correlation coefficient 
was found to be 0.999 for standard curve indicating 
good linearity. The identification was done by IR 
spectra, which suggested the purity of drug within the 
prescribed limit. The comparison of spectra of drug with 
the spectra of polymers Gelatin and Acrypol 934P 
reveals no drug excipients interaction. The melting point 
of the Levofloxacin was found to be 212˚C. Gelatin/ 
Acrypol 934P microspheres of Levofloxacin were 
prepared by Emulsification cross- linking method. The 
effect of polymer concentration, Glutaraldehyde 
concentration and stirring speed was optimized with 
respect to particle size, size distribution and surface 
smoothness. It was found that an increase in stirring 
speed resulted in smaller average particle size and 
decrease in Glutaraldehyde concentration resulted in 
better surface smoothness. Results suggested that the 
stirring speed of 1000RPM was found to be optimum for 
both types of microspheres. An optimum concentration 
of Glutaraldehyde (1% with respect to gelatin mass) was 
a compromise between surface smoothness and in vitro 
digestion of microspheres preparation. Acrypol 934P 
concentration did not show any remarkable effect on 
size and size distribution. Rather it shows a significant 
effect on bioadhesive property and in vitro drug release. 
The percentage yield and drug entrapment efficiency for 
optimized formulations of Gelatin/ Acrypol 
microspheres was found to be 94.6%, 85.43%. The 
average particle size for optimized formulations of 
Gelatin/ Acrypol 934P microspheres were found to be 
41.5µm. Photomicrographs revealed that the 
microspheres were spherical in shape. In vitro drug 
release was found to be controlled in comparison with 
pure drug.  Drug release from Gelatin/ Acrypol 
mucoadhesive microspheres showed more than 75% of 
the drug was released within 8 hrs, while pure drug 
showed complete drug release within 3 hours. This 
suggested controlled delivery of Levofloxacin for longer 
period. Regression analysis revealed that the drug 
release from the microspheres were followed zero order 
kinetics. SEM images suggested spherical shape with 
smooth surface for both type of microspheres 
formulations. Optimized formulations of Gelatin/ 
Acrypol 934P microspheres showed excellent 
mucoadhesivity i.e., 86.5%. Thus, the proposed Gelatin/ 
Acrypol 934P mucoadhesive microspheres might make a 
contribution in complete eradication of Helicobacter 
pylori owing to prolonged stomach residence time and 
small particle size. 
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